A question of capacity
Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more
Nearly three quarters (72.9 per cent) of GPs felt inadequately prepared to deal with the increasing demand for cosmetic surgery.
Over half of the 155 GPs surveyed by GP (54.8 per cent) said the number of queries they received was increasing. Demand for cosmetic surgery is rising in the UK as the stigma and perceptions of cosmetic treatments change, a recent survey by the Harley Medical Group found.
Despite this, just over a quarter of GPs felt adequately trained when asked about cosmetic surgery, with 21 per cent having to tell patients to look on the internet and 59.1 per cent advising them to contact a private hospital when the treatment was not offered on the NHS.
The majority of GPs (63 per cent) would counsel the patients about the reason they wanted surgery.
Breast augmentation was by far the most common query reported by GPs, with treatments associated with obesity, such as liposuction and abdominoplasty also commonly asked about. Facial improvements like rhinoplasty and eye lifts were the third most commonly reported.
But although GPs feel inadequately prepared to deal with questions about the procedure, only 9 per cent would like to provide the service in their practice. A small proportion, (5.2 per cent) already perform cosmetic procedures in their practice.
Read our blog 'Cosmetic surgery loses its lustre'
Comment below and tell us what you think
Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more
The WPBA should be seen as a developmental process, says the RCGP's Dr Jane Mamelok. Read more
Working as an educational supervisor can be stimulating and rewarding, says Dr Alexander Williams. Read more
Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more
Contributed by Dr David Kernick, a GPSI in headache, based in Exeter. Read more
Section 1: Epidemiology and aetiology Read more
Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more
The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more
Comments
Only registered users may comment. Log in now or register for a free account.